Feb 14, 2023 / 03:40PM GMT
David Reed Risinger - SVB Securities LLC, Research Division - Senior MD
Great. So good morning, everyone. Thank you for joining us for this next session with Amgen. It's very much my pleasure on behalf of SVB Securities to host a few of the company's executives.
For those of you who don't know me, I'm Dave Risinger. I cover diversified biopharmaceuticals. And with us today, we have Peter Griffith, who's Executive Vice President and CFO; Susan Sweeney, who's Senior Vice President of Global Marketing Access and Capabilities; and Arvind Sood, who's Vice President of Investor Relations.
I thought it would be great, Peter, to turn it over to you to have you start us off with a few minutes of opening comments to frame the broader picture for Amgen before we transition to discussing some of the commercial opportunities with Susan.
So with that, let me turn it to you, Peter.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Dave, thank you very much. Thank you, SVB Securities. We're always very pleased to join you. So we always started
Amgen Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers